Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

Capricor Therapeutics (NASDAQ:CAPR) saw its stock plummet by 53% on Friday after the U.S. Food and Drug Administration issued a Complete Response Letter (CRL), rejecting the company’s bid for approval ...

A research team collected pain and prescription data from the medical records of 1,282 people with different types of ...

Medical research on muscular dystrophy and myopathy. Read about the promise of stem cell research for muscular dystrophy patients, and successful treatments tested in dogs.

Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...

A Central Texas teen battling muscular dystrophy and complications that landed her in a Fort Worth hospital got a nice ...

The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced ...

Shelby Harmon, a Wilson College student majoring in animal studies with minors in biology and psychology, traveled to ...

The MESA data demonstrated sustained disease stabilization, reinforcing prior ARCH and CANYON findings. Importantly, CANYON participants w ...